{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:37:34Z","timestamp":1785886654087,"version":"3.56.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>AP01, a novel formulation of inhaled pirfenidone, has demonstrated potential for improved efficacy and safety for idiopathic pulmonary fibrosis (IPF) vs. oral pirfenidone. A 72-week phase 1b study, ATLAS, suggested reliable correlations between structural changes revealed by high-resolution computed tomography (HRCT) and functional changes in forced vital capacity (FVC). Correlations between symptom improvement and structural changes are less established. Using ATLAS data, this study aims to investigate correlations between quantitative HRCT scores and changes in patient-reported outcomes (PROs) in AP01-treated patients with IPF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200991) received AP01 50\u00a0mg qd or 100\u00a0mg bid. FVC, quantitative lung fibrosis (QLF), and PRO measures including King\u2019s Brief Interstitial Lung Disease questionnaire (KBILD) assessed functional, structural, and symptomatic changes over 48 weeks. Non-contrast HRCTs were performed at baseline and 24 weeks; improvement was defined as &gt;\u20092% decrease in QLF score.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 69 patients with sufficient quality HRCT scans, similar proportions on both regimens exhibited QLF improvement (50\u00a0mg qd: 16%; 100\u00a0mg bid:16%) and QLF stabilisation (-2% \u2264 \u2206QLF\u2009\u2264\u20092%) (50\u00a0mg qd: 47%; 100\u00a0mg bid: 55%). 100-mg bid subjects with improved QLF exhibited increased mean KBILD total scores from baseline beginning week 8 (8 points) through week 48 (&gt;\u200920 points) (minimal clinically important difference\u2009=\u20095 points).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      A strong and lasting association between structural and symptomatic improvements confirms functional changes with AP01 and supports evaluation of the 100\n                      <jats:sub>-<\/jats:sub>\n                      mg bid dose.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>\n                      AustralianNew Zealand Clinical Trials Registry Identifier ACTRN 12,618,001,838,202 URL:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/www.anzctr.org.au\" ext-link-type=\"uri\">https:\/\/www.anzctr.org.au<\/jats:ext-link>\n                      the trial registration took place before the first patient enrolled trial registration was 12 November 2018 and first patient enrolled on 06 January 2019.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12890-026-04234-x","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T03:35:05Z","timestamp":1774236905000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Improved quality of life, reduced quantitative lung fibrosis in a trial of inhaled pirfenidone for idiopathic pulmonary fibrosis"],"prefix":"10.1186","volume":"26","author":[{"given":"Grace Hyun J.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix A.","family":"Woodhead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepthi","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard M.","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig S.","family":"Conoscenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan G.","family":"Goldin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"issue":"5","key":"4234_CR1","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","volume":"198","author":"G Raghu","year":"2018","unstructured":"Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018;198(5):e44\u201368.","journal-title":"Am J Respir Crit Care Med"},{"issue":"22","key":"4234_CR2","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071\u201382.","journal-title":"N Engl J Med"},{"issue":"1","key":"4234_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/thx.39.1.1","volume":"39","author":"SW Clarke","year":"1984","unstructured":"Clarke SW, Newman SP. Therapeutic aerosols 2\u2013Drugs available by the inhaled route. Thorax. 1984;39(1):1\u20137.","journal-title":"Thorax"},{"issue":"1","key":"4234_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1089\/jamp.2018.1507","volume":"33","author":"JK Khoo","year":"2020","unstructured":"Khoo JK, Montgomery AB, Otto KL, Surber M, Faggian J, Lickliter JD, et al. A Randomized, Double-Blinded, Placebo-Controlled, Dose-Escalation Phase 1 Study of Aerosolized Pirfenidone Delivered via the PARI Investigational eFlow Nebulizer in Volunteers and Patients with Idiopathic Pulmonary Fibrosis. J Aerosol Med Pulm Drug Deliv. 2020;33(1):15\u201320.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"9","key":"4234_CR5","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1136\/thorax-2022-219391","volume":"78","author":"A West","year":"2023","unstructured":"West A, Chaudhuri N, Barczyk A, Wilsher ML, Hopkins P, Glaspole I, et al. Inhaled pirfenidone solution (AP01) for IPF: a randomised, open-label, dose-response trial. Thorax. 2023;78(9):882\u20139.","journal-title":"Thorax"},{"key":"4234_CR6","unstructured":"U.S.Food and Drug Administration (FDA). Multiple Endpoints in Clinical Trials: Guidance for Industry. Silver Spring, MD: U.S. Department of Health and Human Services, Food and Drug Administration; 2022. https:\/\/www.fda.gov\/media\/162416\/download."},{"issue":"6","key":"4234_CR7","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1164\/rccm.202312-2213SO","volume":"209","author":"G Raghu","year":"2024","unstructured":"Raghu G, Ghazipura M, Fleming TR, Aronson KI, Behr J, Brown KK et al. Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) clinical trials: emphasis on \u2018feels, functions, survives\u2019. report of a collaborative discussion in a symposium with direct engagement from representatives of patients, investigators, the national institutes of health, a patient advocacy organization, and a regulatory agency. Am J Respir Crit Care Med. 2024;209(6):647\u2009\u2013\u200969.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"4234_CR8","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1164\/rccm.200412-1756OC","volume":"172","author":"DA Lynch","year":"2005","unstructured":"Lynch DA, Godwin JD, Safrin S, Starko KM, Hormel P, Brown KK, et al. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med. 2005;172(4):488\u201393.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"4234_CR9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1164\/rccm.201803-0444PP","volume":"199","author":"X Wu","year":"2019","unstructured":"Wu X, Kim GH, Salisbury ML, Barber D, Bartholmai BJ, Brown KK, et al. Computed Tomographic Biomarkers in Idiopathic Pulmonary Fibrosis. The Future of Quantitative Analysis. Am J Respir Crit Care Med. 2019;199(1):12\u201321.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"4234_CR10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S2213-2600(19)30262-0","volume":"8","author":"L Richeldi","year":"2020","unstructured":"Richeldi L, Fernandez Perez ER, Costabel U, Albera C, Lederer DJ, Flaherty KR, et al. Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2020;8(1):25\u201333.","journal-title":"Lancet Respir Med"},{"key":"4234_CR11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.2174\/1874306402014010022","volume":"14","author":"L Lancaster","year":"2020","unstructured":"Lancaster L, Goldin J, Trampisch M, Kim GH, Ilowite J, Homik L, et al. Effects of Nintedanib on Quantitative Lung Fibrosis Score in Idiopathic Pulmonary Fibrosis. Open Respir Med J. 2020;14:22\u201331.","journal-title":"Open Respir Med J"},{"key":"4234_CR12","doi-asserted-by":"publisher","first-page":"175346662110042","DOI":"10.1177\/17534666211004238","volume":"15","author":"GHJ Kim","year":"2021","unstructured":"Kim GHJ, Goldin JG, Hayes W, Oh A, Soule B, Du S. The value of imaging and clinical outcomes in a phase II clinical trial of a lysophosphatidic acid receptor antagonist in idiopathic pulmonary fibrosis. Ther Adv Respir Dis. 2021;15:17534666211004238.","journal-title":"Ther Adv Respir Dis"},{"issue":"5 Suppl 62","key":"4234_CR13","first-page":"S26","volume":"28","author":"HG Kim","year":"2010","unstructured":"Kim HG, Tashkin DP, Clements PJ, Li G, Brown MS, Elashoff R, et al. A computer-aided diagnosis system for quantitative scoring of extent of lung fibrosis in scleroderma patients. Clin Exp Rheumatol. 2010;28(5 Suppl 62):S26\u201335.","journal-title":"Clin Exp Rheumatol"},{"key":"4234_CR14","doi-asserted-by":"crossref","unstructured":"Wang XTP, Lo P, Banola A, Kim G, Abtin F, Goldin J, Brown M. High Throughput Lung and Lobar Segmentation by 2D and 3D CNN on Chest CT with Diffuse Lung Disease. In: Stoyanov D, et al. editors. Image Analysis for Moving Organ, Breast, and Thoracic Images. RAMBO BIA TIA 2018. Lecture Notes in Computer Science. Cham: Springer; 2018. p. 202\u2013214.","DOI":"10.1007\/978-3-030-00946-5_21"},{"issue":"4","key":"4234_CR15","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1136\/thorax.58.4.339","volume":"58","author":"SS Birring","year":"2003","unstructured":"Birring SS, Prudon B, Carr AJ, Singh SJ, Morgan MD, Pavord ID. Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax. 2003;58(4):339\u201343.","journal-title":"Thorax"},{"issue":"9","key":"4234_CR16","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1136\/thoraxjnl-2012-201581","volume":"67","author":"AS Patel","year":"2012","unstructured":"Patel AS, Siegert RJ, Brignall K, Gordon P, Steer S, Desai SR, et al. The development and validation of the King\u2019s Brief Interstitial Lung Disease (K-BILD) health status questionnaire. Thorax. 2012;67(9):804\u201310.","journal-title":"Thorax"},{"issue":"1","key":"4234_CR17","doi-asserted-by":"publisher","first-page":"e000363","DOI":"10.1136\/bmjresp-2018-000363","volume":"6","author":"A Sinha","year":"2019","unstructured":"Sinha A, Patel AS, Siegert RJ, Bajwah S, Maher TM, Renzoni EA, et al. The King\u2019s Brief Interstitial Lung Disease (KBILD) questionnaire: an updated minimal clinically important difference. BMJ Open Respir Res. 2019;6(1):e000363.","journal-title":"BMJ Open Respir Res"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-026-04234-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-026-04234-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-026-04234-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:40:22Z","timestamp":1781642422000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12890-026-04234-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4234"],"URL":"https:\/\/doi.org\/10.1186\/s12890-026-04234-x","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"27 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"GHJK holds Patent UC-2013-078-2-LA-EP and has received consulting fees from Voiant and a research grant fund from Boehringer Ingelheim. FAW and CSC are employees of Avalyn Pharma Inc. and hold stock options. DN, HB, and HML are employees of Avalyn Pharma Inc. JGG reports receiving support for his written contributions to the present manuscript from Avalyn Pharma Inc., consulting fees and support for travel to meetings from Boehringer Ingelheim (education advisory board), and consulting fees from Zura. He is also a named inventor on a UCLA-owned patent (UC Patent UC-20132-078-2-LA-US, 2015) and holds stock\/stock options in MedQIA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Local Ethics Committees\/Institutional Review Boards approved the protocol for each site, and all patients provided written informed consent before enrolment. A table presenting Ethics Committees\/Institutional Review Boards and approval IDs\/numbers is provided in Supplemental Table 1.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Consent for publication"}},{"value":"GHJK holds Patent UC-2013-078-2-LA-EP and has received consulting fees from Voiant and a research grant fund from Boehringer Ingelheim. FAW and CSC are employees of Avalyn Pharma Inc. and hold stock options. DN, HB, and HML are employees of Avalyn Pharma Inc. JGG reports receiving support for his written contributions to the present manuscript from Avalyn Pharma Inc., consulting fees and support for travel to meetings from Boehringer Ingelheim (education advisory board), and consulting fees from Zura. He is also a named inventor on a UCLA-owned patent (UC Patent UC-20132-078-2-LA-US, 2015) and holds stock\/stock options in MedQIA.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Competing interests"}}],"article-number":"202"}}